Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

FDM Group trading in line amid ongoing macro uncertainty

(Sharecast News) - FDM Group said in an update on Tuesday that trading in the first quarter of 2025 was in line with expectations, but shares were sliding as it reiterated its cautious approach to recruitment and expenditure amid ongoing macroeconomic and geopolitical uncertainty. The London-listed IT services provider, which was holding its annual general meeting, noted continued hesitancy among some clients, particularly as they awaited clarity on US economic policy.

As of 30 April, the group had 2,366 consultants assigned to client projects, down from 2,578 at the end of December and 3,543 a year earlier.

The board said it was focused on controlling fixed costs and discretionary spending while preserving the capacity to respond to improving demand.

FDM reported a strong balance sheet, with £42m in cash and no debt.

Chair David Lister said the group was confident in its long-term positioning, supported by a global client base and experienced leadership, and sees potential for growth as market conditions recover.

At 0915 BST, shares in FDM Group Holdings were down 5.42% at 235.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.